Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL503067 | 1.00 | DRD2 (0.54) | DRD2DRD3 | |
| SCHEMBL503006 | 1.00 | DRD2 (0.54) | DRD2DRD3 | |
| Hydrochloric Acid SCHEMBL3653333 | 0.98 | DRD2 (0.53) | DRD2DRD3 | |
| Hydrochloric Acid SCHEMBL917502 | 0.98 | DRD2 (0.53) | DRD2DRD3 | |
| SCHEMBL4481944 | 0.90 | — | — | |
| SCHEMBL2602803 | 0.85 | — | — | |
| Hydrochloric Acid SCHEMBL537399 | 0.84 | — | — | |
| SCHEMBL7880438 | 0.83 | DRD2 (0.53) | DRD2DRD3 | |
| SCHEMBL82902 | 0.83 | DRD2 (0.53) | DRD2DRD3 | |
| SCHEMBL366065 | 0.83 | DRD2 (0.53) | DRD2DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 115 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4727591-A1 | SMARCA2 DEGRADERS AND USES THEREOF | Astrazeneca AB (SE) | 2026-04-22 | — | — | EP | disclosed |
| US-12595265-B2 | Inhibitors of activin receptor-like kinase | BLUEPRINT MEDICINES CORPORATION (US) | 2026-04-07 | — | — | US | disclosed |
| EP-4676922-A1 | BIFUNCTIONAL COMPOUNDS CAPABLE OF DEGRADING ANDROGEN RECEPTORS | Astrazeneca AB (SE) | 2026-01-14 | — | — | EP | disclosed |
| EP-4373817-B1 | SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2025-05-21 | — | — | EP | disclosed |
| US-20250051316-A1 | 2-(ARYL-2-YL) MORPHOLINE AND DEUTERATED DERIVATIVE THEREOF, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | SHANGHAI HANSOH BIOMEDICAL CO., LTD. (CN) | 2025-02-13 | — | — | US | disclosed |
| WO-2024256988-A1 | SMARCA2 DEGRADERS AND USES THEREOF | ASTRAZENECA AB (SE) | 2024-12-19 | — | — | WO | disclosed |
| US-20240374606-A1 | SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2024-11-14 | — | — | US | disclosed |
| CN-117700459-B | Synthesis method and application of benzo five-membered C-P ring skeleton monophosphine ligand | 内蒙古大学 | 2024-11-08 | — | — | CN | disclosed |
| WO-2024222860-A1 | SALT OF MORPHOLINE HETEROCYCLIC COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 江苏豪森药业集团有限公司 | 2024-10-31 | — | — | WO | disclosed |
| CN-118852146-A | Crystal form of morpholine heterocyclic compound, and preparation method and application thereof | 江苏豪森药业集团有限公司 | 2024-10-29 | — | — | CN | disclosed |
| US-20110152245-A1 | SUBSTITUTED BENZAMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-06-23 | — | — | US | disclosed |
| US-20110152245-A1 | SUBSTITUTED BENZAMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-06-23 | — | — | US | disclosed |
| US-20110152245-A1 | SUBSTITUTED BENZAMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-06-23 | — | — | US | disclosed |
| WO-2010104193-A2 | INTERMEDIATE COMPOUND FOR SYNTHESIZING PHARMACEUTICAL AGENT AND PRODUCTION METHOD THEREOF | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-09-16 | — | — | WO | disclosed |
| US-20060058329-A1 | Pyrazole inhibitors of the transforming growth factor | SMITHKLINE BEECHAM CORPORATION | 2006-03-16 | — | — | US | disclosed |
| US-20060004051-A1 | Compounds | DODIC NERINA | 2006-01-05 | — | — | US | disclosed |
| EP-1554268-A1 | PYRAZOLE INHIBITORS OF THE TRANSFORMING GROWTH FACTOR | SMITHKLINE BEECHAM CORPORATION (US) | 2005-07-20 | — | — | EP | disclosed |
| EP-1554275-A2 | COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-07-20 | — | — | EP | disclosed |
| WO-2004016606-A1 | PYRAZOLE INHIBITORS OF THE TRANSFORMING GROWTH FACTOR | SMITHKLINE BEECHAM CORPORATION (US) | 2004-02-26 | — | — | WO | disclosed |
| WO-2004013134-A2 | COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-02-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250051316-A1 | 2-(ARYL-2-YL) MORPHOLINE AND DEUTERATED DERIVATIVE THEREOF, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | TAAR1, TAAR5, AVPR2 | DRD2 171/4885DRD3 334/4885 |
| US-20060058329-A1 | Pyrazole inhibitors of the transforming growth factor | SMAD3, SMAD2, TGFBR1 | DRD2 4731/4885DRD3 4348/4885 |
| US-20110152245-A1 | SUBSTITUTED BENZAMIDES | TAAR1, TAAR5, NPY1R | DRD2 596/4885DRD3 1047/4885 |
| US-20240374606-A1 | SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER | PDXK, PGK1, PGK2 | DRD2 4816/4885DRD3 4812/4885 |
| US-12595265-B2 | Inhibitors of activin receptor-like kinase | ACVR1, ACVRL1, ACVR2A | DRD2 807/4885DRD3 1037/4885 |
| US-20060004051-A1 | Compounds | SMAD3, SMAD2, TGFBR1 | DRD2 3809/4885DRD3 3506/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.